A Phase IIB Study to Assess the Efficacy of GSK 249553 [MAGE-A3 ASCI] as Adjuvant Therapy Given to MAGE-3-Positive Patients With Non-Small-Cell Lung Cancer in Stage IB (T2/N0) or II (T1/N1 or T2/N1 or T3/N0), Who Have Had Complete Surgical Resection.

Trial Profile

A Phase IIB Study to Assess the Efficacy of GSK 249553 [MAGE-A3 ASCI] as Adjuvant Therapy Given to MAGE-3-Positive Patients With Non-Small-Cell Lung Cancer in Stage IB (T2/N0) or II (T1/N1 or T2/N1 or T3/N0), Who Have Had Complete Surgical Resection.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2016

At a glance

  • Drugs Zastumotide (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 May 2013 Results published in the Journal of Clinical Oncology.
    • 01 Jul 2011 Primary endpoint 'Disease-free-survival-duration' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top